Bremelanotide (PT-141)
PT-141 · Vyleesi
A centrally acting melanocortin agonist with an indication-specific approved autoinjector.
Mechanism
Melanocortin receptor agonist
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Premenopausal women with acquired, generalized HSDD
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Common as-needed schedule | 1–2 mg | 1–2 mg on use day | As needed; not daily | Several hours before the research window | Subcutaneous | Community-reported |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
The FDA-approved product is a fixed-dose autoinjector. Generic vial math should not be substituted for product labeling.
Important: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
The FDA-approved product is a fixed-dose autoinjector. Generic vial math should not be substituted for product labeling.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
Labeling includes blood-pressure, nausea, pigmentation, interaction and use-frequency warnings.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.